Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | THRA | P10827 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561489 | 0.88 | KDM4E (0.46) | MAPTKDM4EGAAMAPK1TDP1 | |
| SCHEMBL6823917 | 0.81 | HTR7 (0.43) | KDM4EGAAMAPK1TDP1ALDH1A1 | |
| SCHEMBL3565222 | 0.81 | KDM4E (0.49) | KDM4EGAAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3555783 | 0.78 | HTR7 (0.40) | KDM4ETDP1ALDH1A1SMN1; SMN2THRA | |
| SCHEMBL3562648 | 0.78 | KDM4E (0.49) | MAPTKDM4EGAAMAPK1ALDH1A1 | |
| SCHEMBL3560979 | 0.76 | KDM4E (0.48) | MAPTKDM4EGAAMAPK1TDP1 | |
| SCHEMBL6820760 | 0.74 | DRD2 (0.43) | MAPTKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3557902 | 0.74 | HTR6 (0.50) | MAPTKDM4EGAAMAPK1ALDH1A1 | |
| SCHEMBL6820963 | 0.74 | KDM4E (0.46) | KDM4EGAAMAPK1TDP1ALDH1A1 | |
| SCHEMBL3559884 | 0.73 | HTR6 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | MAPT 1145/4885KDM4E 3751/4885GAA 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.